Model Answer

Introduction

India, known as the “pharmacy of the world,” supplies affordable medicines globally. However, repeated reports of Diethylene Glycol (DEG) contamination in cough syrups — leading to child deaths in Madhya Pradesh, Gambia, and Uzbekistan — have highlighted glaring lapses in the nation's drug quality control system. These incidents raise critical questions about regulatory oversight, testing standards, and ethical accountability within the pharmaceutical ecosystem.

Body

1. Systemic Challenges in Ensuring Drug Safety:

   1. Fragmented Regulatory Structure: The Central Drugs Standard Control Organisation (CDSCO) and State Drug Controllers often operate with overlapping roles and poor coordination, leading to inconsistent enforcement.
   2. Inadequate Quality Infrastructure: Many states lack well-equipped testing laboratories, and sampling is often infrequent or selective rather than risk-based.
   3. Weak Compliance Culture: Small and medium drug manufacturers often bypass Good Manufacturing Practices (GMP) due to cost pressures or lack of capacity.
   4. Supply Chain Gaps: Poor traceability of Active Pharmaceutical Ingredients (APIs), including imports from unverified sources, increases contamination risks.
   5. Limited Accountability: Penalties for adulteration and non-compliance remain weak, and legal prosecution is rare.
   6. Export Oversight Issues: Regulatory checks for exported drugs are sometimes less stringent, leading to international embarrassment and loss of trust.

2. Measures to Strengthen Pharmaceutical Quality Control:

   1. Regulatory Reforms: Implement a unified National Drug Regulatory Authority with real-time digital monitoring of manufacturing units.
   2. Risk-Based Inspections: Prioritize inspections of firms producing high-risk products or with a history of violations.
   3. Strengthening Laboratories: Upgrade testing facilities and establish regional National Reference Labs with modern equipment.
   4. Mandate WHO-GMP Certification: Make global quality standards mandatory for both domestic and export markets.
   5. Transparency and Traceability: Introduce a National Drug Quality Database to track product origin, testing results, and recalls.
   6. Capacity Building: Train regulators, pharmacists, and manufacturers in modern quality assurance techniques.
   7. Public Awareness: Strengthen pharmacovigilance through public reporting of adverse drug reactions.

Conclusion/Way Forward

Drug safety is not merely a regulatory issue—it is a public health imperative. The DEG contamination episodes serve as a wake-up call to overhaul India's drug quality ecosystem through stricter enforcement, digital traceability, and a culture of ethical manufacturing. Only by ensuring “Quality at Source” can India sustain its global reputation as a reliable and humane pharmacy of the world.